BCRX earnings analysis
What we found in BCRX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
BioCryst Pharmaceuticals (BCRX) reported strong Q1 2026 earnings with revenue reaching $156.4 million, surpassing estimates and marking a year-over-year increase of 7.5%. EPS for the quarter was reported at 0.14, exceeding expectations and showcasing the company's recovery from previous quarters' losses. Despite a 5.8% decline in ORLADEYO revenue linked to the sale of European operations, strategic licensing agreements and growth in the domestic market helped drive results.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Q1 Revenue Growth
- Total revenue increased to $156.4 million from $145.5 million YoY, a 7.5% increase.
- EPS Over Estimate
- Reported EPS of $0.14 compares favorably against an estimate of $0.10, highlighting an EPS surprise of 40%.
- ORLADEYO Revenue Boost
- Domestic ORLADEYO revenue rose by $25.6 million YoY, indicating strong patient demand despite European business impacts.
- Licensing Revenue Growth
- License revenue increased by $3 million due to quarterly royalty payments from BioCryst Ireland Limited.
- Successful Acquisition
- The merger with Astria provided access to navenibart, now in Phase 3 development, enhancing growth potential.
- Debt Financing Completed
- Secured $400 million from Blackstone to enhance liquidity post-merger.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Increased Operating Loss
- Operating loss of $721.8 million due to non-cash charges related to in-process R&D from the navenibart acquisition.
- Decline in ORLADEYO Revenue
- European ORLADEYO revenue dropped by $11.5 million due to the sale to Neopharmed, impacting overall sales.
- High Debt Load
- Incurred $400 million in debt under the Blackstone Loan Agreement, impacting future financial flexibility.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.14
- Segment
- ORLADEYO
- Segment
- Navenibart
- Segment
- BCX17725
What they said about what is next.
Maintained revenue guidance for full-year 2026 between $635 million and $660 million.
The filing reads better than the one before it.
What came before.
- 10-K · February 26, 2026
- BioCryst describes a rare-disease-focused strategy built around commercialization of ORLADEYO and selective BD to expand a pipeline of oral small molecules and injectable proteins. Financials show a clear inflection in…
- 10-Q · August 6, 2024
- BioCryst reported Q2 revenue of $109.3M (three months ended June 30, 2024) up from $82.5M a year ago, produced operating income of $8.8M versus a $20.7M operating loss in Q2 2023, and delivered a GAAP loss per share of…
- 10-Q · November 8, 2023
- BioCryst reported Q3 revenue of $86,742,000 (up $10,915,000 vs. Q3 2022) and GAAP loss per share of $(0.19) (improved $0.04 vs. $(0.23) in Q3 2022). Product sales drove results ($85,288,000) with very high gross margins…
- 10-Q · May 8, 2023
- BioCryst reported Q1 revenue of $68,778,000, up from $49,923,000 a year earlier, with GAAP net loss narrowing to $(53,333,000) or $(0.28) per share from $(74,196,000) or $(0.40). Gross margin remained very high (product…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BCRX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever